Press release
Type 2 Diabetes Market - See Which Drugs Are Leading in 2025 - Novo Nordisk A/S, Eli Lilly and Company, Viatris Inc., and Teva Pharmaceutical Industries Ltd
Type 2 Diabetes Market
DataM Intelligence has released its latest report on the "Type-2 Diabetes Market Size 2025," providing a detailed analysis of market trends, key growth drivers, competitive landscape, and regional insights. The report includes market size (value and volume), CAGR projections, and emerging opportunities that help businesses identify growth areas and build effective strategies. Backed by data-driven insights and future outlook, this study serves as a valuable resource for companies looking to stay competitive and capitalize on market potential.
Glucagon-like peptide-1 (GLP-1) receptor agonists held a 47.2% market share in the drug type segment of the global Type 2 diabetes market in 2024.
According to the International Diabetes Federation, 588.71 million people worldwide were living with diabetes in 2024, with this number projected to rise to 852.47 million by 2050.
Key Diabetes Drugs in 2025
Novo Nordisk: Semaglutide (subcutaneous and oral), Tirzepatide (Zepbound)
Eli Lilly: Tirzepatide (Mounjaro), orforglipron (under FDA review)
Insulet: Omnipod 5 insulin pump system
Generics and biosimilars expanding access including liraglutide and insulin analogues.
Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://datamintelligence.com/download-sample/type-2-diabetes-market?kb
Ozempic → Novo Nordisk A/S → Sales: US$17,461.62M → U.S. Sales: US$12,217.57M → U.S. Share: 70.0%
Mounjaro → Eli Lilly and Company → Sales: US$11,540.10M → U.S. Sales: US$8,949.90M → U.S. Share: 77.6%
Trulicity → Eli Lilly and Company → Sales: US$5,253.50M → U.S. Sales: US$3,693.80M → U.S. Share: 70.3%
Rybelsus → Novo Nordisk A/S → Sales: US$3,380.98M → U.S. Sales: US$1,566.35M → U.S. Share: 46.3%
Victoza → Novo Nordisk A/S → Sales: US$795.44M → U.S. Sales: US$246.52M → U.S. Share: 31.0%
Key Player:
Novo Nordisk A/S, Eli Lilly and Company., Sanofi, Pfizer Inc., Johnson & Johnson Services, Inc., AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc., Merck & Co., Inc., Viatris Inc., and Teva Pharmaceutical Industries Ltd
Key Industry Developments:
In April 2025, Eli Lilly and Company announced positive Phase 3 trial results for orforglipron, the first oral GLP-1 receptor agonist taken once daily without food or water restrictions, showing a 1.6% A1C reduction from a baseline of 8.0% in type 2 diabetes patients.
In the same month, the FDA approved the generic version of Victoza (liraglutide) for type 2 diabetes treatment.
Forecast Projection:
The global Type-2 Diabetes market is set to witness strong growth from 2025 to 2032. After maintaining steady momentum in 2024, the market is expected to accelerate as key industry players implement strategic initiatives to boost adoption. Companies that adapt to these emerging trends will be well-positioned to capture new opportunities and enhance their revenue potential throughout the forecast period.
Market Intelligence Research Process:
The Type-2 Diabetes Market Report by DataM Intelligence offers a comprehensive analysis built on a mix of primary and secondary research. It explores key factors driving the industry, including government policies, market trends, competitive landscape, technological advancements, and upcoming innovations. This in-depth study uncovers both growth opportunities and potential challenges, helping businesses navigate market fluctuations and make data-driven decisions for sustainable success.
Latest M&A
The Type 2 Diabetes market's M&A activity was valued at around USD 88.9 billion in 2025, with key players like Eli Lilly, Sanofi, Medtronic, and Novo Nordisk actively acquiring companies with innovative technologies. For example, Eli Lilly acquired Protomer Technologies to advance glucose-responsive insulin development.
Lupin acquired diabetes brands ONDERO and ONDERO MET from Boehringer Ingelheim to strengthen its offerings in India.
Buy Now & Get 30% OFF - (Grab 50% OFF on 2+ reports) @ https://www.datamintelligence.com/buy-now-page?report=type-2-diabetes-market?kb
Key Segmentations:
By Drug Type: Dipeptidyl-Peptidase 4 (DPP-4) Inhibitors, Saxagliptin, Sitagliptin, Linagliptin, Alogliptin, Alpha-glucosidase Inhibitors, Acarbose, Miglitol, Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists, Semaglutide, Dulaglutide, Exenatide, Liraglutide, Lixisenatide, Sodium-glucose Transporter 2 (SGLT2) Inhibitors, Canagliflozin, Dapagliflozin, Empagliflozin, Ertugliflozin, Meglitinides, Repaglinide, Nateglinide, Sulfonylureas, Glipizide, Glimepiride, Glyburide, Thiazolidinediones, Rosiglitazone, Pioglitazone, Biguanides (Metformin), Others
By Gender: Male, Female
By Route of Administration: Oral, Parenteral
By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Latest News & Developments
Omnipod 5 by Insulet was approved by the FDA for Type 2 Diabetes patients, with 30% of new users in 2025 having Type 2 Diabetes, reflecting its expanding role in diabetes management.
Novo Nordisk's oral semaglutide (Rybelsus) received a new FDA indication in October 2025 for reducing the risk of major adverse cardiovascular events (MACE) in adults with Type 2 Diabetes at high CV risk, marking a significant advancement.
The 2025 American Diabetes Association (ADA) guidelines emphasize early use of combination therapies, increased CGM use, and consider renal-protective effects of GLP-1 receptor agonists.
Get Customization in the report as per your requirements: https://datamintelligence.com/customize/type-2-diabetes-market?kb
FAQ's
Q1: How large is the Type-2 Diabetes Market?
Ans: The Type-2 Diabetes Market size was valued at US$ 61.50 billion in 2024 and is projected to grow to US$ 124.26 billion by 2033.
Q2: How quickly is the Type-2 Diabetes Market expanding?
Ans: The Type-2 Diabetes Market is forecasted to grow at a CAGR of 8.2% between 2025 and 2032, showing Annual growth momentum
Q3: Which regions are dominating the Type-2 Diabetes Market and which are fastest-growing?
Ans: North America dominating the Type-2 Diabetes market.
FDA Approvals
Notable approvals in 2025 include oral semaglutide for cardiovascular risk reduction, generics for insulin and GLP-1 analogues, and advanced delivery systems enhancing patient adherence.
Additional oral drugs like orforglipron (Eli Lilly) are expected to receive FDA approval soon based on promising Phase 3 data
Have any Query We Will Provide in Detailed @ https://www.datamintelligence.com/enquiry/type-2-diabetes-market?kb
Reimbursement
Reimbursement policies expanded in the US and globally to cover a broader range of diabetes drugs, including GLP-1 receptor agonists and insulin analogues, with new coverage for advanced glucose monitoring.
Medicare and insurance companies are adopting value-based contracts focusing on both glycemic and cardiovascular outcomes to manage costs while improving patient care.
Challenges remain in reimbursement variability across countries and among patient segments, especially in emerging markets.
Get 2-Day Free Trial + 50% OFF DataM Subscription@ https://www.datamintelligence.com/reports-subscription?kb
Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.
Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg
Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com
Linkedin: https://www.linkedin.com/company/datam-intelligence/
Twitter: https://x.com/DataM_Research
About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Type 2 Diabetes Market - See Which Drugs Are Leading in 2025 - Novo Nordisk A/S, Eli Lilly and Company, Viatris Inc., and Teva Pharmaceutical Industries Ltd here
News-ID: 4262176 • Views: …
More Releases from DataM Intelligence 4 Market Research LLP
US Smart Water Valves Market Growth Forecast 2025-2032: Market to Reach USD 5 Bi …
The Global Smart Water Valves Market was valued at US$ 2.7 billion in 2024 and is projected to reach US$ 5.0 billion by 2032, expanding at a CAGR of 8% during 2025-2032. The market growth is driven by increasing adoption of smart water management systems, rapid urbanization, and growing focus on water conservation and leak detection technologies.
Rising investments in smart infrastructure and integration of IoT-enabled monitoring solutions are transforming the…
United States Gas Detection Equipment Market 2025: Industry Developments, Future …
Gas Detection Equipment Market is expected to grow at a CAGR of 5% during the forecast period 2024-2031.
According to DataM Intelligence Comprehensive Report has released its latest report on the "Gas Detection Equipment Market Size 2025," providing a detailed analysis of market trends, key growth drivers, competitive landscape, and regional insights. The report includes market size (value and volume), CAGR projections, and emerging opportunities that help businesses identify growth areas…
US and Europe Forage Seeds Market reaching USD 11.15 billion by 2031 | Corteva A …
The US and Europe forage seeds market reached USD 6.18 billion in 2022 and is expected to reach USD 11.15 billion by 2031, growing at a CAGR of 7.65% during the forecast period 2024-2031, according to DataM Intelligence.
Get a Free Sample PDF of This Report (Get Higher Priority for Corporate Email ID): https://www.datamintelligence.com/download-sample/us-and-europe-forage-seeds-market?jd
Recent Developments (November 2025)
✅ EU Sustainable Fodder Production Scheme - The European Commission launched…
Lycopene Market Set to Soar with Rising Health Awareness and Innovative Applicat …
According to DataM Intelligence, the Lycopene Market is poised for remarkable growth, expected to reach USD 800 billion by 2030, with a robust CAGR of 72% over the forecast period. Lycopene, a powerful antioxidant naturally found in tomatoes and other red fruits, is grabbing attention worldwide due to its promising health benefits and extensive use across food, pharmaceutical, and cosmetic industries.
As consumers increasingly seek natural and functional ingredients to enhance…
More Releases for Diabetes
Major Force in the Diabetes Pen Market 2025: Diabetes Fuels Surge In Demand For …
How Will the Diabetes Pen Market Grow, and What Is the Projected Market Size?
The diabetes pen market is projected to grow from $29.24 billion in 2024 to $31.22 billion in 2025, at a CAGR of 6.8%. Growth is fueled by the rising need for managing diabetes, advancements in diabetes care, and an increasing focus on patient-friendly medication administration tools.
The diabetes pen market is projected to grow strongly, reaching $40.17 billion…
Diabetes Monitoring Devices Market: Regaining Its Glory| Ascensia Diabetes Care, …
The Latest Study Published by HTF MI Research on the "Diabetes Monitoring Devices Market'' evaluates market size, trend and forecast to 2029. The Diabetes Monitoring Devices market study includes significant research data and evidences to be a practical resource document for managers and analysts is, industry experts and other key people to have an easily accessible and self-analysed study to help understand market trends, growth drivers, opportunities and upcoming challenges…
Prevalence of Diabetes Drives Opportunities for Type-2 Diabetes Market
The Type-2 Diabetes Market Analysis, 2023, by MarkNtel Advisors, presents a well-researched, detail-driven, and accurate study for the stakeholders. This analysis entails prominent aspects like trends, & recent developments, drivers, opportunities, challenges, & restraints, among other parameters, influencing the overall industry expansion across different locations. This report comprises data from historic years (2018-21) & the base year (2022) to put together an estimation of the forecast period (2023-28).
According to Type-2 Diabetes Market…
Reverse Diabetes with Dr. Merritt’s Diabetes Reversal Recipe
[November 26, 2020] – People suffering from diabetes always search for ways to lower blood sugar levels in their bodies. Diabetes treatment available costs you hundreds of dollars yearly and also restricts you to a diabetic diet. That hampers your mental health and well-being. Apart from this, eye problems, kidney failure, amputations are some of the physical problems diabetic patients face.
Dr. Marlene Merritt (from the Merritt Wellness Center in…
Diabetes Treatment
Diabetes Treatment is a important way to help manage the healthy ,easy to use and improve the way of the treatment of blood glucose monitoring system.
As living standards improve, an increasing obesity, the Diabetes Treatment has improved peoples living habits, disease control effect, is becoming more and more important.
The global Diabetes Treatment market is valued at 43700 million US$ in 2018 and will reach 58000 million US$ by the end…
Self-Monitoring Blood Glucose Devices Market Study by Advance Application [Type …
The global self-monitoring blood glucose devices market was valued at $7,768 million in 2017 and is projected to reach $10,828 million by 2025 at a CAGR of 4.2% from 2018 to 2025. Monitoring of blood glucose is an essential step in diabetes management. Blood glucose monitoring devices are predominantly used to monitor a patient’s blood glucose level. Self-monitoring blood glucose (SMBG) devices are easy-to-use and enable people to monitor their…
